Present status and thought on tumor immunotherapy and related biomarkers
10.3969/j.issn.1000-8179.2020.11.306
- VernacularTitle: 肿瘤免疫治疗及其相关标记物的研究现状与思考
- Author:
Bo ZHANG
1
Author Information
1. Department of Oncology, Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
Biomarkers;
Immune-related adverse reactions (irAE);
Treatment status;
Tumor immunotherapy
- From:
Chinese Journal of Clinical Oncology
2020;47(11):581-585
- CountryChina
- Language:Chinese
-
Abstract:
Tumor immunotherapy has changed mode for tumor treatment and has gradually developed into the fourth tumor treatment option after surgery, chemotherapy, and radiotherapy. However, the response rate of immunotherapy is limited. Identification of accurate tumor immunotherapy biomarkers as targets or detection and evaluation indicators would be helpful to improve the response rate. Explorations of more effective delivery of immunotherapy would benefit more patients. Prevention and response to immune-related adverse reactions are also necessary. With the development of research, immunotherapy will bring more hope to cancer patients.
